Share

December 2015; 2 (6) ArticleOpen Access

Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease

Andrew L. Mammen, Livia Casciola-Rosen, Lisa Christopher-Stine, Thomas E. Lloyd, Kathryn R. Wagner
First published November 19, 2015, DOI: https://doi.org/10.1212/NXI.0000000000000172
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1836

Share

Article Information

vol. 2 no. 6 e172
DOI: 
https://doi.org/10.1212/NXI.0000000000000172
PubMed: 
26668818
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received June 26, 2015
  • Accepted in final form September 16, 2015
  • First Published November 19, 2015.
Copyright & Usage: 
© 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Andrew L. Mammen, MD, PhD,
    2. Livia Casciola-Rosen, PhD,
    3. Lisa Christopher-Stine, MD, MPH,
    4. Thomas E. Lloyd, MD, PhD and
    5. Kathryn R. Wagner, MD, PhD
  1. Andrew L. Mammen, MD, PhD,
    2. Scientific Advisory Boards:

    1. aTYR pharmaceuticals advisory board Biogen advisory board

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Experimental Neurology, Editorial Board, 2013-Arthritis and Rheumatism, Editorial Board, 2014-

    Patents:

    1. Patented test for anti-HMGCR antibodies that is licensed to INOVA diagnostics

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH, K08

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. Licensed test for anti-HMGCR antibodies to INOVA Diagnostics

    Royalty Payments, Technology or Inventions:

    1. Licensed test for anti-HMGCR antibodies to INOVA Diagnostics

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Livia Casciola-Rosen, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. HMGCR antibody assay

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. R56-A062615 (NIH bridge award- NIAMS)

    Research Support, Academic Entities:

    1. RO1-AR-44684 (NIH grant - NIAMS)

    Research Support, Foundations and Societies:

    1. Jerome L Greene Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. HMGCR antibody ELISA assays (INOVA Diagnostics)

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Lisa Christopher-Stine, MD, MPH,
    4. Scientific Advisory Boards:

    1. (1)Novartis (2) Medimmune (3) Walgreen's/Optioncare (40 Mallinckrodt (40 Idera Pharmaceuticals(

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Inova diagnostics

    Editorial Boards:

    1. NONE

    Patents:

    1. (1) Detection of HMGCoA reductase (HMGCR) Antibodies in Patient Sera

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Mallinckrodt Pharamaceuticals (2) Astellas (3) Ono Pharma UK (4) Marathon Pharmaceuticals

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) NuFactor (2) Walgreens (3) IgG America (4) MedProRx

    Research Support, Government Entities:

    1. 1) NHLBI ?Inflammation and Coronary Endothelial Function (HL120905) DSMB Chair (2) NHLBI ?Inflammatory pathogenesis of coronary atherosclerosis in HIV (HL14023).?

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Donald B. and Dorothy L. Stabler Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. (1) Detection of HMGCoA reductase (HMGCR) Antibodies in Patient Sera, Royalties, 2012

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. (1) McAloon and Friedman, P.C. 2014,2015 (2) Shaub, Ahmuty, Citrin, and Spratt, LLP 2014 (expert witness) (3) The Chartwell Law Offices, LLP (expert witness0

  4. Thomas E. Lloyd, MD, PhD and
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 08/01/2013 -11/30/2016 Sponsor: Novartis Study of efficacy and safety of BYM338 in sporadic inclusion body myositis Role: Site PI, 10% effort

    Research Support, Government Entities:

    1. 04/15/2013-03/31/2018 NIH/NINDS RO1 NS082563 role: PI, 50% effort

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 08/01/2013 ? 07/31/2016 MDA Award 277551 Muscular Dystrophy Association PI: Charlotte Sumner, M.D., Role: Co-PI, 0% effort 08/15-07/17 Axonal transport and retrograde signaling in Drosophila models of c9-ALS Sponsor: Robert Packard Center for ALS Research Role: PI, 0% effort 08/14-07/15 Role of Nuclear Transport Defects in the Pathogenesis of ALS/FTD Sponsor: ALSA $80,000 per year Role: PI, 10%

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Kathryn R. Wagner, MD, PhD
    6. Scientific Advisory Boards:

    1. SAB of SOLID GT, FSH Society, PPMD DSMB of CINRG

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NICHD, NCATS

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Team Saij

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the National Institute of Arthritis and Musculoskeletal and Skin Diseases (A.L.M.), NIH, Bethesda; the Departments of Neurology (A.L.M., L.C.-S., T.E.L., K.R.W.), Medicine (L.C.-R., L.C.-S.), and Neuroscience (T.E.L., K.R.W.), Johns Hopkins University School of Medicine, Baltimore; and The Hugo W. Moser Research Institute (K.R.W.), Kennedy Krieger, Baltimore, MD.
  1. Correspondence to Dr. Mammen: andrew.mammen{at}nih.gov
View Full Text

Article usage

Article usage: November 2015 to August 2023

AbstractFullPdfSource
Nov 20159523Highwire
Dec 20153092859Highwire
Dec 201505737pmc
Jan 20161121017Highwire
Jan 2016012179pmc
Feb 20168414317Highwire
Feb 201608535pmc
Mar 2016571210Highwire
Mar 201608147pmc
Apr 20164286Highwire
Apr 201609239pmc
May 201638156Highwire
May 201607029pmc
Jun 201638206Highwire
Jun 201605118pmc
Jul 20164375Highwire
Jul 201604914pmc
Aug 201636245Highwire
Aug 201605620pmc
Sep 201623186Highwire
Sep 201605520pmc
Oct 201630266Highwire
Oct 201604115pmc
Nov 201613239Highwire
Nov 201602712pmc
Dec 201620217Highwire
Dec 20160648pmc
Jan 201719149Highwire
Jan 201704113pmc
Feb 201718277Highwire
Feb 201704117pmc
Mar 201720237Highwire
Mar 201706317pmc
Apr 201730153Highwire
Apr 2017164953pmc
May 201713162Highwire
May 201783944pmc
Jun 201720121Highwire
Jun 201793944pmc
Jul 201718122Highwire
Jul 201744246pmc
Aug 201720410Highwire
Aug 201742828pmc
Sep 20171555Highwire
Sep 2017134344pmc
Oct 20172654Highwire
Oct 2017102232pmc
Nov 20171681Highwire
Nov 201773034pmc
Dec 20170193Highwire
Jan 20181142Highwire
Feb 20184258Highwire
Mar 20184434Highwire
Apr 20180359Highwire
Apr 201861923pmc
May 201801437Highwire
Jun 201801748Highwire
Jun 201832023pmc
Jul 201841165Highwire
Aug 201811034Highwire
Aug 201853041pmc
Sep 20181672Highwire
Oct 20180677Highwire
Nov 2018112512Highwire
Dec 2018214511Highwire
Jan 2019110014Highwire
Feb 201988713Highwire
Mar 20192317Highwire
Apr 201963611Highwire
May 201952410Highwire
Jun 201925210Highwire
Jul 201934114Highwire
Aug 201932312Highwire
Sep 20192227Highwire
Oct 20194266Highwire
Nov 20192379Highwire
Dec 20191264Highwire
Jan 202022814Highwire
Feb 2020213210Highwire
Mar 202042713Highwire
Apr 20200157Highwire
May 202021819Highwire
Jun 202012215Highwire
Jul 202022624Highwire
Aug 20202247Highwire
Sep 202042617Highwire
Oct 202014220Highwire
Nov 202012516Highwire
Dec 202042118Highwire
Jan 202124822Highwire
Feb 20211236Highwire
Mar 20213376Highwire
Apr 20213328Highwire
May 20214287Highwire
Jun 20212286Highwire
Jul 202131813Highwire
Aug 20210359Highwire
Sep 202173211Highwire
Oct 202112523Highwire
Nov 202162225Highwire
Dec 202123511Highwire
Jan 202257310Highwire
Feb 202225011Highwire
Mar 202244717Highwire
Apr 202224813Highwire
May 202244016Highwire
Jun 20221499Highwire
Jul 20223336Highwire
Aug 202275411Highwire
Sep 202224615Highwire
Oct 202235516Highwire
Nov 202256526Highwire
Dec 20221399Highwire
Jan 202354313Highwire
Feb 20233348Highwire
Mar 202313933Highwire
Apr 202321813Highwire
May 202323311Highwire
Jun 20233335Highwire
Jul 202362615Highwire
Aug 20234378Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles